🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Blood Cancer Journal is consistently in top 3-4 heme journals that publish original hematology research. BCJ is part of Nature Portfolio Follow us Blood Cancer Journal for the latest updates. Mohamad Mohty Sagar Lonial MD marivi mateos Naseema Gangat nature.com/bcj/

Lymphoma Microenvironment Archetype Profiles (LymphoMAPs). Just presented by David Russler-Germain, MD/PhD at #18icml International Conference on Malignant Lymphoma, now available online in Cancer Cell. #lmsm WashU Medicine MD Anderson Cancer Center. cell.com/cancer-cell/fu…

Hashtags to Access Health Information [6/15/15] - via Matthew Katz, MD 🇺🇸🟦 @Symplur ow.ly/QI3wb comments by: @mstory123

Ontologies Symplur Healthcare Hashtag Project -CTO, OTO, HTO, Cardiology, Pathology, Radiology, Urology ow.ly/ll4530csaDm

Octothorpe - Episode 145 [Nov 16, 2014] 99 Percent Invisible ow.ly/6BJm50CrnZM HT @n8pennel

Our ⁦MD Anderson Cancer Center⁩ experience Technical and Clinical Validity of Assessing Measurable Residual Disease by Multicolor Flow Cytometry in an Unselected Acute Myeloid Leukemia Patient Cohort - ⁦Arch Pathol Lab Med⁩ #MRD #leusm #hemepath #AML pubmed.ncbi.nlm.nih.gov/40522873/

Flerlage et al • GLOW data nod LPHL • completely resected 1A, RT assoc with ⬆️ PFS compared with observation • unresected - ABVD-RT & RT do v well • no infield relapses if RT given Great work which significantly informs practice. #18ICML #ICML25 #lymsm

ICYMI: tafa-R^2 approved by FDA for R/R FL with at least one prior line of systemic therapy. #18ICML #lymsm fda.gov/drugs/resource…

Masterful lecture from David Scott BC Cancer on DLBCL biology One of many highlight slides below - David’s draft of a genomics-informed classification of aggressive B-cell lymphomas #18ICML #lymsm

David Scott’s BC Cancer algorithm for treatment of newly-diagnosed DLBCL based on recent Canadian recommendation for polatuzumab reimbursement for ABC-subtype DLBCL #lymsm #18ICML Ash Alizadeh, MD/PhD 🇺🇸

A nice slide that integrates mutational landscape, COO, DZsig & lymphgen among double hit lymphomas #18ICML #lymsm

Mosun in 1L FL #18ICML - 76 pts, ORR 95%, CR 82% - 1-yr PFS 89%, OS 99% - CRS mostly G1, 3% req'd hospitalization for infx - 1 death d/t COVID during tx Looking forward to longer f/u. #lymsm #tcellrx

Top Influencers of #18ICML {transient; 7d - but new hashtag; 6/19/25}👉 Ajay Major, MD, MBA David Russler-Germain, MD/PhD Eddie Cliff Owhofasa Agbedia, MD, MPH, FACP Liz Brem Mike Thompson, MD, PhD, FASCO Michael Green, PhD Alfredo Rivas-Delgado Lymphoma Hub symplur.com/healthcare-has… via Symplur #ICML2025 #lymsm

Hematology Tag Ontology (HTO) - Mike Thompson, MD, PhD, FASCO Matthew Katz, MD 🇺🇸🟦 Audun Utengen Symplur Intro: symplur.com/blog/introduci… List: symplur.com/healthcare-has… #ASHsm #18ICML #ICML2025 ICML Conference {work in progress}

Organizing Online Health Content: Developing Hashtag Collections for Healthier Internet-Based People and Communities [Jun 28, 2019] Matthew Katz, MD 🇺🇸🟦 et al. JCO Clinical Cancer Informatics ow.ly/AxNP30p1P6g #BPDCN #leusm #lymsm #mdssm #mmsm #mpnsm #wmsm #18ICML #ICML2025 ICML Conference

Impressive early data for VIPOR in mantle cell lymphoma, including in patients with TP53-aberrant disease #18ICML #lymsm

Philippe Giguère BC Cancer Ash Alizadeh, MD/PhD 🇺🇸 Adam Raymakers David Russler-Germain, MD/PhD International Conference on Malignant Lymphoma Here’s an updated version of our table - in addition the POLARIX Asian extension cohort found the same thing, plus our observational cohort of >700 patients presented at ASH. So 11/12 studies (7/8 trials, POLARGO being the first exception) show the same trend #18ICML

#ImmunoOnc #CardioOnc ICI-myocarditis